Xencor traded at $19.84 this Wednesday August 5th, decreasing $0.08 or 0.40 percent since the previous trading session. Looking back, over the last four weeks, Xencor lost 33.24 percent. Over the last 12 months, its price rose by 164.89 percent. Looking ahead, we forecast Xencor to be priced at 19.78 by the end of this quarter and at 18.55 in one year, according to Trading Economics global macro models projections and analysts expectations.
Xencor, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The Company uses its engineering capabilities to enable its understanding of protein structure and interactions to design XmAb technologies and develop candidates with properties. Its antibody design is focused on the segment of antibodies that interact with target antigens. It is focused on the Fc domain, which is the part of an antibody that interacts with various segments of the immune system and controls antibody structure. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Plamotamab, XmAb717, Vibecotamab, Tidutamab, XmAb841, XmAb104, XmAb306, XmAb104, XmAb564 and XmAb698.